期刊文献+

小剂量青黄散及补肾健脾方联合雄激素治疗儿童难治性血细胞减少

Low-dose Qinghuang Powder and Bushen Jianpi Recipe Combined with Androgen in Treatment of Refractory Cytopenia in Children
下载PDF
导出
摘要 目的:分析小剂量青黄散及补肾健脾方联合雄激素对儿童难治性血细胞减少(refractory cytopenia of children,RCC)患儿的疗效及安全性。方法:回顾分析2012年1月至2018年1月就诊于中国中医科学院西苑医院血液科门诊被诊断为RCC,且首次接受小剂量青黄散及补肾健脾方联合雄激素治疗3个月及以上的27例患儿资料。比较治疗前及治疗6、12个月后外周血白细胞(white blood cell,WBC)计数、中性粒细胞(neutrophile granulocyte,ANC)计数、血红蛋白(hemoglobin,HGB)计数、血小板(platelet,PLT)计数及骨髓原始细胞数的变化,分析患儿治疗反应及外周血三系细胞的改善情况,并记录期间发生的不良反应及相应处理方案。结果:小剂量青黄散及补肾健脾方联合雄激素治疗RCC患儿6、12个月时有效率分别为70.4%和81.5%(P>0.05)。治疗6个月时,总体外周血三系细胞的获效率HGB>PLT>ANC(P<0.05);治疗12个月时,三者获效率比较,差异无统计学意义(P>0.05)。治疗12个月内,HGB计数持续且显著升高(P<0.01),PLT、ANC计数仅在治疗前6个月时较治疗前升高(P<0.01,P<0.05)。治疗12个月内,轻度不良反应发生率为11.1%。结论:小剂量青黄散及补肾健脾方联合雄激素可作为RCC患儿一种行之有效的治疗方案;本方案治疗RCC患儿可使外周血HGB获效率更早,计数提升也更显著。 Objective:To analyze the efficacy and safety of low-dose Qinghuang Powder and Bushen Jianpi Recipe combined with androgen in children with refractory cytopenia of children (RCC).Methods:A retrospective analysis of the RCC from the Department of Hematology,Xiyuan Hospital of China Academy of Chinese Medical Sciences from January 2012 to January 2018,and the first treatment of small dose of Qinghuang Powder and Bushen Jianpi Recipe combined with androgen for 3 months and The above 27 cases of children.Comparison of peripheral blood white blood cell (WBC)count,neutrophile granulocyte (ANC) count,hemoglobin (HGB) count,and platelet (PLT) count before and after treatment for 6 and 12 months.And the changes of the number of blast cells in the bone marrow,analyze the treatment response of the children and the improvement of the peripheral blood three-line cells,and record the adverse reactions and corresponding treatment plans during the period.Results:The effective rates of low-dose Qinghuang Powder and Bushen Jianpi Recipe combined with androgen in the treatment of children with RCC at 7 and 12 months were 70.4%and 81.5%,respectively (P>0.05).At 6 months of treatment,the overall peripheral blood three-line cell harvesting efficiency HGB>PLT>ANC (P<0.05);at 12 months of treatment,the three obtained efficiency comparison,the difference was statistically significant (P>0.05).Within 12 months of treatment,the HGB count continued and significantly increased (P<0.01),and the PLT and ANC counts were only increased at 6 months before treatment compared with before treatment (P<0.01,P<0.05).The incidence of mild adverse reactions was 11.1%within 12 months of treatment.Conclusion:Low-dose Qinghuang Powder and Bushen Jianpi Recipe combined with androgen can be an effective treatment for children with RCC.The treatment of children with RCC can make the peripheral blood HGB more efficient and the count increase is more significant.
作者 王德秀 付中学 麻柔 李柳 许勇钢 杨秀鹏 杜宇 王洪志 WANG Dexiu;FU Zhongxue;MA Rou;LI Liu;XU Yonggang;YANG Xiupeng;DU Yu;WANG Hongzhi(Graduate School of China Academy of Chinese Medical Sciences,Beijing China100700;Xiyuan Hospital Affiliated to China Academy of Chinese Medical Sciences,Beijing China 100091)
出处 《中医学报》 CAS 2019年第12期2626-2629,共4页 Acta Chinese Medicine
基金 国家自然科学基金面上项目(81774140) 国家自然科学基金青年科学基金项目(81503429)
关键词 儿童难治性血细胞减少 青黄散 补肾健脾方 雄激素 白细胞 中性粒细胞 血红蛋白 血小板 refractory cytopenia in children Qinghuangsan Bushen Jianpi Recipe androgen white blood cells neutrophils hemoglobin platelets
  • 相关文献

参考文献11

二级参考文献98

  • 1马军,王建祥,主编.造血系统疾病临床诊疗规范教程[M].北京:北京大学医学出版社,2009:548. 被引量:8
  • 2Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96( 12):3671--3674. 被引量:1
  • 3Ulrich G, Norbert G, Corinna S, et al. Validation of the WHO proposal for a new classifications of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk a Res 2000;25(12) : 983---993. 被引量:1
  • 4Tsuda H, Yamasaki H. Type Ⅰ and type Ⅱ T-cells profiles in aplastic anemia and refractory anemia. Am J Hematol 2000;64 (4) : 271--274. 被引量:1
  • 5Ohyashiki K, Ohyashiki JH, Iwabuchi A, et al. Clinical aspects, cytogenetics and disease evolution in myelodysplastic syndromes. Leuk Lymphoma 1996 ;23 ( 5-6 ) : 409--415. 被引量:1
  • 6Haase D, Fonatsch C, Freund M, et al. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol 1995 ;70(4) : 171--187. 被引量:1
  • 7谢晓恬,应大明.小儿再生障碍性贫血诊疗建议[J].中国小儿血液与肿瘤杂志,2007,12(5):236-240. 被引量:26
  • 8Vanlet P, Horny HP, Bennet JM, et al. Definitions and standards in the diagnosis and treatment of myelodysplatic syndromes : Con- sensus statements and report from a working conference[ J ]. Leuk Res,2007,31 : 727 -736. 被引量:1
  • 9Greenberg P, Cox C, LeBeau MM, et al. International senring sys- tem for evaluating prognosis in myelodysplestic syndromes [ J ]. Blood,1997,89 : 2079 - 2088. 被引量:1
  • 10Steensma DP, Baer MR, Slack JL, et al. Muhicenter study of decitabine administered daily forSdays everygweeks to adults with Myelodysplastic syndromes:the alternative dosing for outpatients treatment (ADOPT) trial[ J ]. J Clin Oneol, 2009,27 ( 23 ) : 3842 - 3848. 被引量:1

共引文献371

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部